Emerging treatments for essential thrombocythemia - Wikidata - awgldk - TriplyDB

Emerging treatments for essential thrombocythemia

Emerging treatments for essential thrombocythemia

http://www.wikidata.org/entity/Q35683853

about

The Hepatocyte Growth Factor (HGF)/Met Axis: A Neglected Target in the Treatment of Chronic Myeloproliferative Neoplasms?

P2860

Q38239580-913A7397-FCD2-4637-86FE-5B03F73A3E39

P2860

Emerging treatments for essential thrombocythemia

http://www.wikidata.org/entity/Q35683853

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

Emerging treatments for essential thrombocythemia

@ast

Emerging treatments for essential thrombocythemia

@en

type

label

Emerging treatments for essential thrombocythemia

@ast

Emerging treatments for essential thrombocythemia

@en

prefLabel

Emerging treatments for essential thrombocythemia

@ast

Emerging treatments for essential thrombocythemia

@en

P1433

Q35683853-945211C8-736E-4C72-8A8C-9350BC8ACA43

P1476

Q35683853-234DF3C7-2E42-43BA-B509-4789BAF69A41

P2093

Q35683853-4B765704-4C14-4018-AF3D-1AC2A2CC78A6

Q35683853-CE9BBE78-EAD0-411B-AA10-C74E1CEDBFCB

P2860

Q35683853-05460417-7C0E-4959-B0C7-CDB4A0FC21C9

Q35683853-069E0BED-324F-450E-B52C-308959CFA39F

Q35683853-107119A8-6A36-40AB-B6F6-F57372D11ED7

Q35683853-1CDC3F99-881E-48BC-BAA1-2DCDCFA35542

Q35683853-283375B1-CC1C-4572-996A-654283FB48A8

Q35683853-303BB764-95FF-4AA0-92BE-D17842C5F804

Q35683853-3A0581E8-F0E5-4FD3-BE33-90C781F56C0A

Q35683853-497936ED-F895-42FA-8134-4FE46FCF9C62

Q35683853-4D408477-4C9B-4471-82FD-33EC3C54C644

Q35683853-5255C261-F28B-42BE-B0BB-66640493BCC4

P304

Q35683853-B9C71993-C7F2-41D0-A6C9-6C2C84F5271A

P31

Q35683853-72184046-F8FE-43F8-89F2-D41D0BF0C335

P356

Q35683853-BA5CE946-6080-4481-9764-36C368B87C93

P478

Q35683853-9491A796-5ED8-45F1-B173-563C4764AC48

P577

Q35683853-3F7E2FD2-9E49-4D02-8CF2-9B2F4F1AA1F2

P698

Q35683853-EF6519D3-291E-40C2-B613-BA7C9985B0FF

P932

Q35683853-C563EA5F-881D-409E-BD13-4AE43D15E520

P356

P1433

Journal of Blood Medicine

P1476

Emerging treatments for essential thrombocythemia

@en

P2093

Claire Harrison

http://www.w3.org/2001/XMLSchema#string

Steven Okoli

http://www.w3.org/2001/XMLSchema#string

P2860

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes

Reticulin accumulation in essential thrombocythemia: prognostic significance and relationship to therapy

Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia

Bone marrow pathology in essential thrombocythemia: interobserver reliability and utility for identifying disease subtypes

Guideline for investigation and management of adults and children presenting with a thrombocytosis

A pilot study of the Histone-Deacetylase inhibitor Givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms.

The histone deacetylase inhibitor ITF2357 reduces production of pro-inflammatory cytokines in vitro and systemic inflammation in vivo

MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort.

Pharmacokinetics, safety and inducible cytokine responses during a phase 1 trial of the oral histone deacetylase inhibitor ITF2357 (givinostat).

Treatment-related risk factors for transformation to acute myeloid leukemia and myelodysplastic syndromes in myeloproliferative neoplasms

P304

151-159

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/JBM.S19053

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P577

2011-12-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22287874

http://www.w3.org/2001/XMLSchema#string

P932

3262348

http://www.w3.org/2001/XMLSchema#string